JP2011507853A - 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ - Google Patents
緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ Download PDFInfo
- Publication number
- JP2011507853A JP2011507853A JP2010539503A JP2010539503A JP2011507853A JP 2011507853 A JP2011507853 A JP 2011507853A JP 2010539503 A JP2010539503 A JP 2010539503A JP 2010539503 A JP2010539503 A JP 2010539503A JP 2011507853 A JP2011507853 A JP 2011507853A
- Authority
- JP
- Japan
- Prior art keywords
- dose
- tanaproget
- hours
- progestin
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 239000000583 progesterone congener Substances 0.000 claims abstract description 123
- 230000003637 steroidlike Effects 0.000 claims abstract description 69
- 241001465754 Metazoa Species 0.000 claims abstract description 46
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 84
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 claims description 81
- 229950001471 tanaproget Drugs 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 66
- 239000000262 estrogen Substances 0.000 claims description 63
- 229940011871 estrogen Drugs 0.000 claims description 63
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 34
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 34
- 229960002568 ethinylestradiol Drugs 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 26
- 230000001568 sexual effect Effects 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- WVAVALYHMUJZPG-UHFFFAOYSA-N spiro[cyclohexane-1,3'-indole] Chemical compound C1CCCCC21C1=CC=CC=C1N=C2 WVAVALYHMUJZPG-UHFFFAOYSA-N 0.000 description 11
- 239000003826 tablet Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- -1 nausea Chemical class 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 230000002254 contraceptive effect Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 239000003433 contraceptive agent Substances 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229960001390 mestranol Drugs 0.000 description 3
- 229960003248 mifepristone Drugs 0.000 description 3
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940095053 emergency contraceptive drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000003408 postcoitus contraceptive agent Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- OUGSRCWSHMWPQE-WMZOPIPTSA-N (13s,14s)-3-hydroxy-13-methyl-7,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4CCC2=C1 OUGSRCWSHMWPQE-WMZOPIPTSA-N 0.000 description 1
- UWYDUSMQFLTKBQ-KSZLIROESA-N (13s,14s,17r)-13-methyl-6,7,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CC[C@H]3O)C)=C4CCC2=C1 UWYDUSMQFLTKBQ-KSZLIROESA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FABGTKBXHAEVKL-OWSLCNJRSA-N (8s,13s,14s,17s)-13-methyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3=CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FABGTKBXHAEVKL-OWSLCNJRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FTFSACSWQUILGG-UHFFFAOYSA-N 1-methyl-5-(2-sulfanylidenespiro[1h-indole-3,1'-cyclohexane]-5-yl)pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)C23CCCCC3)C2=C1 FTFSACSWQUILGG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- XRARAIRGCAJWCW-UHFFFAOYSA-N 3-(5-chlorothiophen-2-yl)spiro[cyclohexane-1,3'-indole] Chemical compound S1C(Cl)=CC=C1C1CC2(C3=CC=CC=C3N=C2)CCC1 XRARAIRGCAJWCW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RUGRUJOUJQTWRW-UHFFFAOYSA-N 4-spiro[cyclohexane-1,3'-indole]-5'-ylthiophene-2-carbonitrile Chemical compound C(#N)C1=CC(=CS1)C=1C=C2C3(C=NC2=CC=1)CCCCC3 RUGRUJOUJQTWRW-UHFFFAOYSA-N 0.000 description 1
- GYRIYQJAXONYMT-UHFFFAOYSA-N 5-spiro[cyclohexane-1,3'-indole]-5'-yl-1H-pyrrole-2-carbonitrile Chemical compound C(#N)C1=CC=C(N1)C=1C=C2C(=CC1)N=CC21CCCCC1 GYRIYQJAXONYMT-UHFFFAOYSA-N 0.000 description 1
- BOWCANNUHXFDOY-UHFFFAOYSA-N 5-spiro[cyclohexane-1,3'-indole]-5'-ylthiophene-2-carbonitrile Chemical compound C(#N)C1=CC=C(S1)C=1C=C2C3(C=NC2=CC=1)CCCCC3 BOWCANNUHXFDOY-UHFFFAOYSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- HHMBGTCECNHKOW-UHFFFAOYSA-N C(#N)C1=CC(=C(S1)C=1C=C2C3(C=NC2=CC=1)CCCCC3)C Chemical compound C(#N)C1=CC(=C(S1)C=1C=C2C3(C=NC2=CC=1)CCCCC3)C HHMBGTCECNHKOW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003575 estradiol acetate Drugs 0.000 description 1
- FHXBMXJMKMWVRG-SLHNCBLASA-N estradiol acetate Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)C)=CC=C3[C@H]21 FHXBMXJMKMWVRG-SLHNCBLASA-N 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 229960003836 estriol succinate Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940094984 other estrogen in atc Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000002379 progesterone receptor modulator Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 229960001424 quinestrol Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000522 vaginal cream Substances 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US828707P | 2007-12-20 | 2007-12-20 | |
| PCT/US2008/013933 WO2009082478A1 (en) | 2007-12-20 | 2008-12-19 | Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014118432A Division JP2014193918A (ja) | 2007-12-20 | 2014-06-09 | 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507853A true JP2011507853A (ja) | 2011-03-10 |
| JP2011507853A5 JP2011507853A5 (https=) | 2013-02-14 |
Family
ID=40799234
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539503A Pending JP2011507853A (ja) | 2007-12-20 | 2008-12-19 | 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ |
| JP2014118432A Withdrawn JP2014193918A (ja) | 2007-12-20 | 2014-06-09 | 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014118432A Withdrawn JP2014193918A (ja) | 2007-12-20 | 2014-06-09 | 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090170823A1 (https=) |
| EP (1) | EP2234491A4 (https=) |
| JP (2) | JP2011507853A (https=) |
| AU (1) | AU2008341138A1 (https=) |
| BR (1) | BRPI0819571A2 (https=) |
| CA (1) | CA2710293A1 (https=) |
| EA (1) | EA201070715A1 (https=) |
| IL (1) | IL206465A0 (https=) |
| WO (1) | WO2009082478A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012523446A (ja) * | 2009-04-14 | 2012-10-04 | ラボラトワール・アシュエールア−ファルマ | オンデマンド避妊方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007338843B2 (en) * | 2006-12-20 | 2013-05-09 | Teva Women's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| FR2937862B1 (fr) * | 2008-11-03 | 2010-11-19 | Mohammed Ridha Chakroun | Kit contraceptif |
| US20100155594A1 (en) | 2008-12-23 | 2010-06-24 | Goldman Mildred M | Mass spectrometry assay for estrogenic compounds |
| KR20160013098A (ko) | 2013-05-21 | 2016-02-03 | 프리딕티브 테라퓨틱스, 엘엘씨 | 치료제 및 그 사용 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511890A (ja) * | 1996-05-16 | 2000-09-12 | ガイネティックス・インコーポレイテッド | 緊急避妊キット |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684534A (en) * | 1985-02-19 | 1987-08-04 | Dynagram Corporation Of America | Quick-liquifying, chewable tablet |
| DK174724B1 (da) | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
| DK0650480T3 (da) * | 1992-07-01 | 2002-05-13 | Ortho Pharma Corp | 1-Arylsulfonyl-3-phenyl-1,4,5,6-tetrahydropyridaziner |
| DE4344463A1 (de) * | 1993-12-22 | 1995-06-29 | Schering Ag | Kombinationsprodukt zur Kontrazeption |
| US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
| IL115738A (en) * | 1994-10-24 | 2002-05-23 | Schering Ag | Competitive progesterone antagonists for regulating female fertility as required |
| ZA9510926B (en) * | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| FR2772617B1 (fr) * | 1997-12-19 | 2001-03-09 | Besins Iscovesco Lab | Comprime de progesterone et son procede de preparation |
| US6368625B1 (en) | 1998-08-12 | 2002-04-09 | Cima Labs Inc. | Orally disintegrable tablet forming a viscous slurry |
| US6060078A (en) | 1998-09-28 | 2000-05-09 | Sae Han Pharm Co., Ltd. | Chewable tablet and process for preparation thereof |
| US6667050B1 (en) * | 1999-04-06 | 2003-12-23 | Galen (Chemicals) Limited | Chewable oral contraceptive |
| US6399593B1 (en) * | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
| US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6660726B2 (en) * | 2000-03-10 | 2003-12-09 | Endeavor Pharmaceuticals | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| HU227198B1 (en) * | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
| US20030158432A1 (en) * | 2002-01-08 | 2003-08-21 | Leonard Thomas W. | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| JP2005526064A (ja) * | 2002-03-11 | 2005-09-02 | シエーリング アクチエンゲゼルシャフト | 受精能制御およびホルモン置換療法における使用のためのプロゲステロン受容体調整活性を有する５−｛２−ヒドロキシ−３−１−（３−トリフルオロメチルフェニル）−シクロプロピル−プロピオニルアミノ｝−フタリドおよび関連化合物 |
| CN1662241A (zh) | 2002-06-25 | 2005-08-31 | 惠氏公司 | 环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途 |
| IL165395A0 (en) * | 2002-06-25 | 2006-01-15 | Wyeth Corp | Use of thio-oxubdile derivatives in treatment of hormone-related conditions |
| JP2005535628A (ja) * | 2002-06-25 | 2005-11-24 | ワイス | Ｐｒモジュレーターとしてのシクロチオカルバメート誘導体 |
| AU2003258047A1 (en) * | 2002-10-11 | 2004-05-04 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
| US20060008408A1 (en) * | 2002-10-17 | 2006-01-12 | Nexen Nano Tech. Co., Ltd. | Fibrous nano-carbon and preparation method thereof |
| WO2004100857A2 (en) * | 2003-05-07 | 2004-11-25 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
| AR047398A1 (es) * | 2003-11-24 | 2006-01-18 | Wyeth Corp | Acoplamiento cruzado carbono- carbono catalizado por metales de transicion sobre soportes solidos |
| EP1691746B1 (en) * | 2003-12-08 | 2015-05-27 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
| CN1672685A (zh) * | 2004-03-26 | 2005-09-28 | 董可娟 | 一种新的避孕药物 |
| US7399870B2 (en) * | 2004-03-30 | 2008-07-15 | Wyeth | Synthesis of pyrrole-2-carbonitriles |
| ES2317223T3 (es) * | 2004-04-08 | 2009-04-16 | Wyeth | Derivados de tioamida como moduladores del receptor de progesterona. |
| BRPI0509159B1 (pt) * | 2004-04-08 | 2014-08-26 | Wyeth Llc | Processo para preparar um composto de fenoxicicloalquila |
| JP4950027B2 (ja) * | 2004-04-08 | 2012-06-13 | ワイス・エルエルシー | チオアミド不純物を最小限に抑えるための方法 |
| TW200604137A (en) * | 2004-04-27 | 2006-02-01 | Wyeth Corp | Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls |
| BRPI0510278A (pt) | 2004-04-27 | 2007-10-30 | Wyeth Corp | método para produzir compostos, produto, e, composto |
| MXPA06012403A (es) | 2004-04-27 | 2007-01-17 | Wyeth Corp | Purificacion de moduladores de receptor progesterona. |
| US20060009428A1 (en) * | 2004-07-07 | 2006-01-12 | Wyeth | Cyclic progestin regimens and kits |
| GT200500183A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| MX2007001812A (es) * | 2004-08-13 | 2007-03-26 | Wyeth Corp | Derivados de tanaproget, metabolitos, y usos de los mismos. |
| CN101027321A (zh) * | 2004-08-20 | 2007-08-29 | 惠氏公司 | 孕酮受体结构 |
| JP4197684B2 (ja) * | 2005-03-23 | 2008-12-17 | 株式会社東芝 | 携帯無線機 |
| CN101166521A (zh) * | 2005-04-28 | 2008-04-23 | 惠氏公司 | 通过湿制粒法制备包含微粒化他那普戈特的组合物 |
| AU2006241189B2 (en) * | 2005-04-28 | 2012-01-19 | Wyeth Llc | Purified form of tanaproget |
| MX2007013467A (es) * | 2005-04-28 | 2008-01-21 | Wyeth Corp | Tanaproget micronizado y composiciones que contienen el mismo. |
| CN101166532B (zh) * | 2005-04-28 | 2011-06-22 | 惠氏公司 | 微粒化的他那普戈特、组合物及其制备方法 |
| CN101166736B (zh) * | 2005-04-28 | 2013-02-06 | 惠氏公司 | 他那普戈特的多晶型ⅱ |
| MX2007013450A (es) * | 2005-04-29 | 2008-01-21 | Wyeth Corp | Procedimniento de preparacion de oxindoles y tio-oxindoles 3,3-disustituidos. |
| KR100733419B1 (ko) * | 2005-04-30 | 2007-06-29 | 주식회사 하이닉스반도체 | 내부전원 생성장치 |
| UY29527A1 (es) * | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| US20060293295A1 (en) * | 2005-05-13 | 2006-12-28 | Kai Strothmann | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate |
| US8663681B2 (en) * | 2005-05-26 | 2014-03-04 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and methods of making and using the same |
| CA2610767C (en) | 2005-06-09 | 2014-09-23 | Wyeth | Tanaproget compositions containing ethinyl estradiol |
| WO2007000056A1 (en) * | 2005-06-28 | 2007-01-04 | Casper Robert F | Aromatase inhibitors for emergency contraception |
| PE20070341A1 (es) * | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
| PE20070404A1 (es) * | 2005-07-29 | 2007-05-10 | Wyeth Corp | Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona |
| PE20070182A1 (es) * | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
| TW200740782A (en) * | 2005-09-01 | 2007-11-01 | Tanabe Seiyaku Co | Thiomorpholine compound and process for preparing the same |
| US7319152B2 (en) * | 2005-09-19 | 2008-01-15 | Wyeth | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators |
| US20070066628A1 (en) * | 2005-09-19 | 2007-03-22 | Wyeth | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators |
| DE102005050729A1 (de) * | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
| US20070093548A1 (en) * | 2005-10-25 | 2007-04-26 | Wyeth | Use of progesterone receptor modulators |
| US20070213526A1 (en) * | 2006-03-07 | 2007-09-13 | Wyeth | Purification of progesterone receptor modulators |
| TW200810231A (en) * | 2006-08-11 | 2008-02-16 | Hon Hai Prec Ind Co Ltd | Antenna device |
| AU2007338843B2 (en) * | 2006-12-20 | 2013-05-09 | Teva Women's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
-
2008
- 2008-12-19 BR BRPI0819571A patent/BRPI0819571A2/pt not_active IP Right Cessation
- 2008-12-19 CA CA2710293A patent/CA2710293A1/en not_active Abandoned
- 2008-12-19 AU AU2008341138A patent/AU2008341138A1/en not_active Abandoned
- 2008-12-19 EA EA201070715A patent/EA201070715A1/ru unknown
- 2008-12-19 EP EP08865187A patent/EP2234491A4/en not_active Withdrawn
- 2008-12-19 WO PCT/US2008/013933 patent/WO2009082478A1/en not_active Ceased
- 2008-12-19 US US12/339,329 patent/US20090170823A1/en not_active Abandoned
- 2008-12-19 JP JP2010539503A patent/JP2011507853A/ja active Pending
-
2010
- 2010-06-17 IL IL206465A patent/IL206465A0/en unknown
-
2014
- 2014-06-09 JP JP2014118432A patent/JP2014193918A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511890A (ja) * | 1996-05-16 | 2000-09-12 | ガイネティックス・インコーポレイテッド | 緊急避妊キット |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013027178; Ｃｏｎｔｒａｃｅｐｔｉｏｎ，２００６，Ｖｏｌ．７４，ｐ．４１４-４１８ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012523446A (ja) * | 2009-04-14 | 2012-10-04 | ラボラトワール・アシュエールア−ファルマ | オンデマンド避妊方法 |
| JP2016188232A (ja) * | 2009-04-14 | 2016-11-04 | ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ | オンデマンド避妊方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201070715A1 (ru) | 2011-02-28 |
| IL206465A0 (en) | 2010-12-30 |
| WO2009082478A1 (en) | 2009-07-02 |
| CA2710293A1 (en) | 2009-07-02 |
| BRPI0819571A2 (pt) | 2019-09-24 |
| JP2014193918A (ja) | 2014-10-09 |
| AU2008341138A1 (en) | 2009-07-02 |
| US20090170823A1 (en) | 2009-07-02 |
| EP2234491A4 (en) | 2010-12-22 |
| EP2234491A1 (en) | 2010-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5951480B2 (ja) | オンデマンド避妊方法 | |
| US20130089574A1 (en) | Method of preventive on-demand hormonal contraception | |
| JP2014193918A (ja) | 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ | |
| US20130090318A1 (en) | Once-a-month method of contraception | |
| US11793669B2 (en) | Combination therapy intravaginal rings | |
| MD3310345T2 (ro) | Comprimată orodispersabilă ce conține estetrol | |
| JP6796693B2 (ja) | 抗プロゲスチンの膣内送達用の製剤と方法 | |
| AU2020200027A1 (en) | Compositions and Methods for Non-Toxic Delivery of Antiprogestins | |
| CA2888377C (en) | Methods and compositions for treating progesterone-dependent conditions | |
| AU2015200367A1 (en) | Dosage regimens and pharmaceutical compositions and packagse for emergency contraception | |
| US20120232043A1 (en) | Lubiprostone for obstetrical or gynecological applications | |
| CN104168902A (zh) | 阴道内给药非类固醇抗炎药物美洛昔康和吡罗昔康用于中断女性排卵过程的用途 | |
| OA21723A (en) | Combination therapy intravaginal rings. | |
| EP4465939A1 (en) | Combination therapy intravaginal rings | |
| Rabe | Contraception-Update and trends | |
| JP2005519963A (ja) | 長期サイクルのエストロゲンおよびスルファターゼ阻害プロゲストゲン避妊レジメン | |
| WO2022207631A1 (en) | Methods for providing late luteal contraception | |
| Greydanus et al. | Contraceptives | |
| HK1168530B (en) | Method for on-demand contraception |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111216 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121211 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130605 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130904 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130911 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140210 |